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Introduction: The epidermal growth factor receptor (EGFR) ty-
rosine kinase inhibitors (TKIs) gefitinib and erlotinib are gaining an
increasing role in the management of advanced non-small cell lung
cancer (NSCLC). There is mounting interest in the benefit of
administering a second TKI after failure of the first TKI, especially
in Asian patients, in whom they are expected to be more efficacious.
Methods: We did a retrospective analysis of patients receiving both
gefitinib and erlotinib in our institution during a 2-year period.
Patients were to have received the second TKI after progressive
disease on the first TKI. EGFR gene mutation analysis was done on
patient tumor samples.
Results: Fourteen patients were included in the analysis, all of
whom received erlotinib after progression on gefitinib. Chinese race,
females, never-smokers, and adenocarcinoma subtype were predom-
inant in their respective categories. Disease control rate was 64.3%
(9 of 14) for gefitinib. Disease control rate for erlotinib administered
after progression on gefitinib was 35.7% (5 of 14). All patients who
achieved disease control with erlotinib after progression on gefitinib
were never-smokers with adenocarcinoma subtype, who had prior
disease control on gefitinib. Presence of EGFR mutations predicted
for disease control with gefitinib, and for disease control with erlotinib
after gefitinib failure.
Conclusion: A significant proportion of typical gefitinib-sensitive
Asian NSCLC patients can have disease control with erlotinib after
gefitinib failure. The role of subsequent administration of a second
EGFR TKI after failure of the first TKI in advanced NSCLC should
be further pursued.
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The epidermal growth factor receptor (EGFR) tyrosinekinase inhibitors (TKIs) gefitinib and erlotinib are rou-
tinely used for the treatment of advanced non-small cell lung
cancer (NSCLC). Erlotinib was shown to prolong survival in
chemotherapy pretreated patients in the phase III BR.21 trial,1
whereas gefitinib did the same for the Asian patient subgroup
in the ISEL study.2 Gefitinib has also been used in the
first-line setting in Japanese and Korean patients with impres-
sive results.3,4 The EGFR TKIs are known to have higher
response rates in Asian NSCLC patients, females, nonsmok-
ers, and those with adenocarcinoma histologic subtype.5–7
Responses were also found to be correlated with the presence
of somatic mutations in the kinase domain of the EGFR
gene,8,9 which are found to occur with greater frequency in
Asian patients.7 Despite the excellent initial response, disease
progression usually occurs after a median time of 4 to 6
months, after which no good treatment options exist for these
patients.
It would be therefore be desirable if there was a role for
the subsequent use of a second TKI after failure of the first
TKI in the management of this difficult disease. As small
molecule oral agents, their attractiveness lies not only in the
ease of administration but also in their tolerability compared
with conventional chemotherapy. There were anecdotal re-
ports of clinical activity seen with the second TKI after
failure of the first TKI,10,11 although others suggested no role
for this.12 A retrospective study was conducted with the
primary objective of assessing the disease control rate of the
second TKI after failure of the first. Secondary objectives
were to characterize the clinical, pathologic, and molecular
features of patients benefiting from a second TKI.
PATIENTS AND METHODS
Patients
After institutional approval, patients at the National
University Hospital who received both gefitinib and erlotinib
from January 2005 to December 2006 were identified through
the electronic pharmacy record system, and a retrospective
review of case files and radiographic records was undertaken.
Patients included in the analysis had histologically or cyto-
logically proven advanced NSCLC who received erlotinib
following disease progression on gefitinib. We included pa-
tients who received the second TKI immediately after stop-
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ping the first TKI, as well as those who received the second
TKI any length of time after stopping the first TKI, with or
without conventional chemotherapy being administered be-
tween TKIs. Patients excluded were those who received the
second EGFR TKI for reasons other than disease progression
on the first TKI, such as toxicity or financial reasons or those
who received erlotinib before gefitinib. Response assessment
was from review of patient records and radiographic studies
including chest roentgenograms and computed tomographic
scans. Disease control was defined as radiographic evidence
of improvement or stability, associated with clinical allevia-
tion or stability of symptoms as assessed by the treating
physician, and continuation of drug treatment. Progression
was defined as a radiographic worsening of existing lesions or
the appearance of new lesions. As patients with peripheral
adenocarcinoma often have a large or even predominant
component of nonmeasurable disease (subcentimeter miliary
nodules, reticulonodular infiltrates, or pneumonic pattern) on
imaging,13 the use of conventional response criteria such as
RECIST14 was considered unsuitable in such patients.15
EGFR Mutation Analysis
Formalin-fixed, paraffin-embedded tumor samples of
the cases were obtained from the Departments of Pathology,
National University Hospital and Tan Tock Seng Hospital,
Singapore. DNA was extracted from 5 m sections of each
sample as described previously.16 Mutations in the tyrosine
kinase domain (exons, 18–21) of EGFR were detected using
partially denaturing high-performance liquid chromatography
as described previously.17
Statistical Analysis
Duration of disease control was defined as the number
of days that the patient received the respective TKI up to the
point of documented disease progression. Survival was cal-
culated from the time of diagnosis to death or the last follow-up
date. Disease control rates were compared between variables of
interest using Fisher exact test.
RESULTS
We identified 18 patients with advanced NSCLC who
received both gefitinib and erlotinib in the course of their
treatment. Four patients were excluded from further analysis,
because three patients did not receive the second EGFR TKI
for progressive disease on the first TKI and one patient
received erlotinib prior to gefitinib. The remaining 14 patients
who received erlotinib after prior progression on gefitinib
were analyzed (Figure 1). The median age was 56 years, and
there was a majority of Chinese, females, and nonsmokers.
Eight of 14 patients had adenocarcinoma histologic subtype,
1 had squamous-cell carcinoma, 2 had bronchioloalveolar
carcinoma (on tissue diagnosis), and 3 patients were NSCLC
not otherwise specified. The majority of patients had florid
lung metastases in the form of subcentimeter nodules, often
in a miliary pattern, reticulonodular infiltrates, or pneumonic
shadows (Table 1).
Gefitinib was used as first-line systemic treatment in 9
of 14 patients whereas erlotinib was used later in the course
of the disease, with 9 of 14 patients receiving it as fourth-line
treatment and beyond (Table 2). The dose of gefitinib was
250 mg daily, and that of erlotinib was 150 mg daily, in all
patients. Thirteen patients also received conventional cyto-
toxic chemotherapy, with a median of two lines administered
(range, 1–5).
Disease control for gefitinib was seen in 9 of 14 patients
(64.3%). In the 9 patients who received gefitinib as first-line
treatment, disease control was seen in 6 (66.7%). Overall
disease control rate for erlotinib as second TKI was seen in 5
of 14 patients (35.7%). Of the 9 patients who achieved prior
disease control with gefitinib, 5 (55.6%) subsequently also
achieved disease control with erlotinib (Figure 1). Of the 5
patients who did not achieve prior disease control with
gefitinib, none achieved disease control with subsequent
erlotinib (p  0.09).
We analyzed the other baseline and treatment charac-
teristics of the 5 patients who showed benefit from receiving
TABLE 1. Patient Characteristics
Characteristic n Percent
Total patients 14 100.0
Median age, yr 56
Range, yr 40–73
Sex
Male 4 28.6
Female 10 71.4
Race
Chinese 12 85.7
Malay 1 7.1
Indian 1 7.1
Smoking status
Never/nonsmoker 13 92.9
Exsmoker 1 7.1
Histology
Adenocarcinoma 8 57.1
BAC 2 14.3
Squamous 1 7.1
Non-small cell unspecified 3 21.4
Metastases sites at presentation
Thoracic-only 7 50.0
Extrathoracic 7 50.0
Bones 4 28.6
Liver 3 21.4
Brain 1 7.1
Abdominal lymph nodes 2 14.3
BAC, bronchioloalveolar carcinoma.FIGURE 1. Analysis of treatment results.
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erlotinib after gefitinib failure (Tables 3 and 4). All patients
were never-smokers who had adenocarcinoma subtype. All
had responded to prior gefitinib. Three of the 5 patients had
dramatic radiographic responses to gefitinib, including sig-
nificant improvements in nonmeasurable disease. Median
duration of disease control in these 5 patients for gefitinib was
227 days (range, 197–537), and subsequently to erlotinib was
97 days (range, 50–238). Dramatic radiographic improve-
ment to erlotinib was seen in two patients, which we illustrate
in Figure 2. One patient had no change in 2-monthly com-
puted tomographic scans of lung lesions previously progress-
ing on gefitinib, until 8 months later. Disease control was
associated with symptomatic improvement or stability in all
patients. All five patients ultimately had progressive dis-
ease on erlotinib. Four of the five patients had conven-
tional chemotherapy (one or 2 lines) in between the dif-
ferent TKI treatments, with a “TKI-free interval” of between 89
to 388 days.
Chemotherapy was administered in between first and
second TKI treatments in 8 of 14 patients. Five patients
received two different regimens, 2 patients received one
regimen, and 1 patient received three different regimens of
conventional chemotherapy in the interval between gefitinib
cessation and erlotinib commencement. The regimens were
carboplatin plus gemcitabine (4 patients), pemetrexed (4
patients), docetaxel (4 patients), carboplatin plus vinorelbine
(1 patient), S-1 (1 patient), and irinotecan plus capecitabine (1
patient). The median number of chemotherapy cycles admin-
istered in these patients between gefitinib cessation and erlo-
tinib commencement was 6 (range, 2–9). Disease control was
achieved by at least one regimen of chemotherapy in 5 of
these 8 patients. We did not find any association between
disease control with chemotherapy during the “TKI-free in-
terval” and disease control with the second TKI, in both the
entire group as well as in the subgroup achieving disease
control with the first TKI.
EGFR mutations were detected in 8 of 14 patients
(57.1%). The mutations in 7 of 8 patients included previously
described sensitizing EGFR mutations, such as exon 19
deletions and the L858R substitution. Four patients had
deletions, three patients had substitutions (including 1 patient
with 2 substitutions) and one patient had both deletion and
substitution. EGFR mutations predicted for disease control
with gefitinib. Eight of eight patients (100.0%) with EGFR
mutations achieved disease control versus 1 of 6 patients
(16.7%) with wild-type EGFR (p  0.003). EGFR mutations
were also associated with disease control with erlotinib. Five
of eight patients (62.5%) with EGFR mutations achieved
TABLE 3. Baseline Characteristics of Patients Benefiting from a Second EGFR TKI
Patient
No. Age Sex Smoking Status Race Histology EGFR Mutation
1 40 M Never Chinese Adenocarcinoma 747:del 21bp (del L747-A755, S)
2 50 F Never Chinese Adenocarcinoma 746:del 15bp (del E746-A750)
3 70 F Never Chinese Adenocarcinoma 833:TTGGTG (L833V), 858:CTGCGG (L858R)
4 68 M Never Indian Adenocarcinoma 868:GAGGTG (E868V)
5 62 F Never Chinese Adenocarcinoma 746:del 15bp (del E746-A750), 851:GTCGTT(V851V)
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; M, male; F, female.
TABLE 4. Treatment Characteristics of Patients Benefiting from a Second EGFR TKI
Patient
No.
TKI
Sequence
Gefitinib Erlotinib
Conventional
Chemotherapy
No. of Lines
TKI-free
Interval
(d)
Survival from
Diagnosis (d)
Line of
Treatment DC Duration of DC (d)
Line of
Treatment DC
Duration of
DC (d)
1 G before E 2nd Yes 197 5th Yes 50 5 105 690 (DOD)
2 G before E 2nd Yes 354 4th Yes 50 2 92 690 (DOD)
3 G before E 1st Yes 227 2nd Yes 238 2 0 911 (AWD)
4 G before E 1st Yes 226 3rd Yes 97 2 89 674 (DOD)
5 G before E 1st Yes 537 4th Yes 198 2 388 1276 (AWD)
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; G, gefitinib; E, erlotinib; DC, disease control; DOD, died of disease; AWD, alive with disease.
TABLE 2. Treatment Characteristics
Treatment n Percent
Gefitinib
1st-line 9 64.3
2nd-line 2 14.3
3rd-line 2 14.3
4th-line 1 7.1
Erlotinib
1st-line 0 0.0
2nd-line 4 28.9
3rd-line 1 7.1
4th-line 9 64.3
Conventional chemotherapy 13 92.9
Median no. of lines 2
Range 1–5
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disease control with erlotinib after gefitinib failure, compared
with 0 of 6 patients (0.0%) with wild-type EGFR (p  0.03).
DISCUSSION
Both gefitinib and erlotinib have been in routine use in
Asian patients with NSCLC for the several years, but little is
known about the efficacy of a second reversible EGFR TKI
after disease progression on the first. A case report by Garfield10
showed response to erlotinib after gefitinib failure in a male
smoker with squamous-cell carcinoma, whereas Choong11 re-
ported response to gefitinib after erlotinib failure in a never-
smoker female with adenocarcinoma. However, Viswanathan12
suggested that there was no role for the subsequent usage of
erlotinib after gefitinib failure in five patients which included
four females with prolonged responses to gefitinib.
Although EGFR sensitizing mutations and clinical re-
sponses to EGFR TKIs are known to occur more frequently
in Asian patients,7 there has not been any conclusive bench or
clinical evidence to suggest that use of erlotinib after pro-
gressive disease on gefitinib or vice versa would be beneficial
in this group of patients. In fact, both EGFR TKIs share the
same mechanism of EGFR blockade and are hence thought to
be cross resistant.18,19 Furthermore, the acquisition of resis-
tance mutations such as T790M implied a potential loss of
sensitivity to both TKIs.20–22
A recent publication of a phase II trial by Cho and
colleagues22 showed a disease control rate of 29.6% in
NSCLC patients treated with erlotinb after gefitinib failure. It
was reported that higher disease control and response rates
with subsequent erlotinib were associated with patients who
lacked EGFR mutations and achieved stable disease on ge-
fitinib. It was proposed that patients who responded initially
to gefitinib and subsequently progressed were less likely to
benefit from erlotinib due to the acquisition of secondary
mutations, in particular T790M, which would confer resis-
tance on both drugs. However, there may be a concern if the
RECIST14 criteria was applied to patients in whom a large or
predominant component of disease was nonmeasurable.13,15
Hotta et al.23 found that disease stability as assessed by conven-
tional criteria, was associated with survival benefit in patients on
gefitinib, whereas Comis18 commented on the lack of
correlation of response rates with survival. The dramatic
responses seen in Figure 2 illustrate the inadequacy of
RECIST criteria in assessing the predominant nonmeasur-
able components in these patients.
In the current study, evidence for clinical benefit in a
number of Asian NSCLC patients treated with erlotinib after
progression on gefitinib was seen. All five cases in our study
were patients who had responded to prior gefitinib, and all
had the characteristics of never-smoker, adenocarcinoma sub-
type, and EGFR gene mutations. Two of the patients showed
dramatic responses on imaging (Figure 2), lasting for dura-
tions of 50 and 198 days. The disease control rate of erlotinib
after gefitinib failure was similar to that in Cho’s study.22
However, we found that the patients who had disease control
with erlotinib were typical gefitinib-sensitive NSCLC pa-
tients with most of them harboring classic sensitizing EGFR
mutations.
There could be several explanations for this finding.
Noncross-resistance of EGFR tyrosine kinase to gefitinib and
erlotinib is the first possibility. It has been proposed that the
different survival outcomes in the BR.211 and ISEL2 studies
attest to the qualitative differences between gefitinib and
erlotinib. The potential for cross-resistance conferred by
acquired secondary mutations like T790M could be abrogated
by other unknown mutations conferring differential sensitiv-
ity. An example of differential sensitivity to erlotinib and
gefitinib was shown in a case report by the discovery of the
novel E884K mutation on exon 22.11 The mechanism of
acquired resistance has also not been explained by the T790M
mutation in all cases,24 hence nonoverlapping susceptibil-
ity of gefitinib and erlotinib to acquired resistance is a
consideration.
It is possible heterogenous malignant clones within the
same patient could harbor different mutation status and EGFR
TKI-sensitivity.25 A patient may benefit from a second EGFR
TKI if the progressive component on the first EGFR TKI at a
different site (e.g., brain metastases) was controlled by radio-
therapy, whereas the original EGFR TKI-sensitive clone re-
mained sensitive and continued to respond on EGFR TKI
resumption.26 However, this was not the situation in any of the
FIGURE 2. Computed tomographic scans of two patients
(nos. 1 and 5—see Tables 3 and 4) demonstrating dramatic
responses of miliary and reticulonodular lung disease with
erlotinib. Both patients had prior progression on gefitinib
with new subcentimeter lung nodules.
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five patients in our study. All five patients had disease control
with erlotinib in the lungs, which was the same site that showed
disease progression on gefitinib.
Another possibility is the loss of acquired-resistance after
a “TKI-free interval.”26 Conventional chemotherapy given after
first-TKI failure may also result in reduction of TKI-resistant
clones, leaving the TKI-sensitive ones to be further controlled by
a second TKI “rechallenge” subsequently.26 Four of the five
patients in our series received conventional chemotherapy dur-
ing “TKI-free intervals” of between 89 and 388 days. However,
we could not demonstrate an association between disease control
with chemotherapy during the “TKI-free interval” and disease
control with the second TKI in our small group of patients.
There is a possibility that erlotinib can salvage gefitinib
failures by sheer difference in drug potency, since erlotinib
(150 mg) is administered at its maximum-tolerated dose
whereas gefitinib (250 mg) is administered at about one third
its maximum-tolerated dose.18 However, this mechanism is
not borne out by the lack of difference in clinical efficacy
between 250 and 500 mg daily dosing for gefitinib in previ-
ous studies.5,6 Furthermore, responses to gefitinib 250 mg
daily dosing after disease progression on erlotinib 150 mg
daily dosing have also been reported.11,27
In conclusion, we found evidence for disease control
with erlotinib after gefitinib failure in a significant proportion
of typical gefitinib-sensitive Asian patients with NSCLC. We
think our results may apply to other non-Asian patients who
harbor typical mutations for EGFR TKI response. The role of
administering a second EGFR TKI after failure of the first
TKI in advanced NSCLC warrants further development.
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